GM-5022

GM-5022
Clinical data
Other namesGM5022
Routes of
administration		Oral[1][2][3]
Drug classPsychoplastogen
ATC code
  • None

GM-5022 is a non-hallucinogenic psychoplastogen which is under development for the treatment of depressive, anxiety, and other neurological disorders.[1][4][2][5][6][3] It is taken orally.[1][2][3] The drug's specific mechanism of action and chemical structure do not appear to have been disclosed yet.[1][4] GM-5022 is under development by Gilgamesh Pharmaceuticals.[1][4][3] As of May 2026, a Phase 1 study is currently evaluating the safety, tolerability, and pharmacokinetics of GM-5022 in healthy volunteers.[7]

See also

References

  1. 1 2 3 4 5 "GM 5022". AdisInsight. Springer Nature Switzerland AG. 4 December 2024. Retrieved 1 August 2025.
  2. 1 2 3 "Gilgamesh Pharma". The Psychedelic Pulse. 11 July 2024. Retrieved 1 August 2025. GM-5022: In the IND enabling phase, this oral neuroplastogen aims to treat depression and anxiety without causing hallucinations. It represents a new class of treatments that could significantly improve patient outcomes.
  3. 1 2 3 4 Barrie R (14 May 2024). "AbbVie makes a play for psychiatric treatments with $2bn Gilgamesh collaboration". Pharmaceutical Technology. Retrieved 1 August 2025. The pharma company is also working on an investigational new drug (IND) application for an oral non-hallucinogenic neuroplastogen named GM-5022.
  4. 1 2 3 "Delving into the Latest Updates on GM-5022 with Synapse". Synapse. 8 May 2025. Retrieved 1 August 2025.
  5. ↑ Bratulic A (13 May 2024). "AbbVie wagers up to $2B on Gilgamesh's approach to psychedelics – minus the trip". firstwordpharma.com. Retrieved 1 August 2025. Gilgamesh's internal pipeline features one neuroplastogen: GM-5022, an oral non-hallucinogenic compound in early development for depression and anxiety.
  6. ↑ Barton C (31 July 2025). "Neuroplastogens: A novel approach to treat neurological diseases". pharmaphorum. Retrieved 1 August 2025. GM-5022, a pre-clinical non-hallucinogenic oral neuroplastogen in development for depression, anxiety, and other mental health disorders.
  7. ↑ "A three-part study of GM 5022 in healthy adults, looking at safety, side effects, how the body processes the medicine, how the medicine works, and the effects of different doses and food". www.isrctn.com. Retrieved 2026-05-04.


This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.